JP2020535124A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535124A5
JP2020535124A5 JP2020515000A JP2020515000A JP2020535124A5 JP 2020535124 A5 JP2020535124 A5 JP 2020535124A5 JP 2020515000 A JP2020515000 A JP 2020515000A JP 2020515000 A JP2020515000 A JP 2020515000A JP 2020535124 A5 JP2020535124 A5 JP 2020535124A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020515000A
Other languages
Japanese (ja)
Other versions
JP7402792B2 (ja
JPWO2019067503A5 (https=
JP2020535124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052797 external-priority patent/WO2019067503A1/en
Publication of JP2020535124A publication Critical patent/JP2020535124A/ja
Priority to JP2023142246A priority Critical patent/JP2023164918A/ja
Publication of JP2020535124A5 publication Critical patent/JP2020535124A5/ja
Publication of JPWO2019067503A5 publication Critical patent/JPWO2019067503A5/ja
Application granted granted Critical
Publication of JP7402792B2 publication Critical patent/JP7402792B2/ja
Priority to JP2025235397A priority patent/JP2026031721A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020515000A 2017-09-26 2018-09-26 多発性骨髄腫を治療するための新規なusp7阻害剤 Active JP7402792B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023142246A JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2025235397A JP2026031721A (ja) 2017-09-26 2025-12-05 多発性骨髄腫を治療するための新規なusp7阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563375P 2017-09-26 2017-09-26
US62/563,375 2017-09-26
PCT/US2018/052797 WO2019067503A1 (en) 2017-09-26 2018-09-26 NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023142246A Division JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤

Publications (4)

Publication Number Publication Date
JP2020535124A JP2020535124A (ja) 2020-12-03
JP2020535124A5 true JP2020535124A5 (https=) 2023-09-12
JPWO2019067503A5 JPWO2019067503A5 (https=) 2023-09-12
JP7402792B2 JP7402792B2 (ja) 2023-12-21

Family

ID=65903565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020515000A Active JP7402792B2 (ja) 2017-09-26 2018-09-26 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2023142246A Pending JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2025235397A Pending JP2026031721A (ja) 2017-09-26 2025-12-05 多発性骨髄腫を治療するための新規なusp7阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023142246A Pending JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2025235397A Pending JP2026031721A (ja) 2017-09-26 2025-12-05 多発性骨髄腫を治療するための新規なusp7阻害剤

Country Status (6)

Country Link
US (2) US11465983B2 (https=)
EP (1) EP3687537A4 (https=)
JP (3) JP7402792B2 (https=)
AU (1) AU2018342089B2 (https=)
CA (1) CA3072353A1 (https=)
WO (1) WO2019067503A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3072353A1 (en) 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. Usp7 inhibitors for treating multiple myeloma
JP7508449B2 (ja) * 2018-10-22 2024-07-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Usp7の阻害
MX2021006542A (es) * 2018-12-06 2021-07-07 Almac Discovery Ltd Inhibidores de la usp19 para usarse en terapia.
EP3965749A4 (en) * 2019-05-06 2023-06-21 Valo Health, Inc. ESCAPEMENT OF USP19
EP4110393A1 (en) 2020-02-28 2023-01-04 Immunologik GmbH Inhibitors of human deubiquitinases for the treatment of coronaviral infections
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用
GB202104097D0 (en) * 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053924A1 (en) * 1998-04-17 1999-10-28 Kyowa Hakko Kogyo Co., Ltd. Analgetic agent
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
EP3253765A1 (en) * 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
HK1248220A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
US9938300B2 (en) * 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
CA3072353A1 (en) 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. Usp7 inhibitors for treating multiple myeloma
JP7508449B2 (ja) 2018-10-22 2024-07-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Usp7の阻害

Similar Documents

Publication Publication Date Title
BR112021012222A2 (https=)
BR112021008873A2 (https=)
BR122022006221A2 (https=)
BR122022015534A2 (https=)
BR122022002075A2 (https=)
JP2020535124A5 (https=)
BR122022005529A2 (https=)
BR122022016585A2 (https=)
BR212020012832U2 (https=)
BR202018071071U8 (https=)
BR202018008879U2 (https=)
BR202018007669U2 (https=)
BR202018006247U2 (https=)
BR202018004136U2 (https=)
BR202018002487U2 (https=)
BR202018002069U2 (https=)
CN304436538S (https=)
CN304434112S (https=)
CN304433972S (https=)
CN304394983S9 (https=)
CN304388867S9 (https=)
CN304267588S9 (https=)
CN304201967S8 (https=)
CN303588531S9 (https=)
CN304433999S (https=)